RIOT

SEC Filing Summary: AspenBio Pharma, Inc. (10-Q)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for AspenBio Pharma, Inc. for the period ended March 31, 2011. The company is a biopharmaceutical firm focused on developing diagnostic tests (specifically AppyScore for acute appendicitis) and animal health products (BoviPure LH and FSH). The filing notes that the company is a smaller reporting company and a shell company check was marked "No".

Key Financial Metrics

Note: Gross margin for Q1 2011 was approximately 87%, compared to 54% in Q1 2010.

Material Changes vs. Prior Period

• Revenue Decline: Sales decreased by 32% ($45,000) due to a strategic decision to suspend antigen production to focus resources on appendicitis and single-chain animal product development.
• Expense Reduction: Operating expenses decreased by approximately $1.05 million. Research and Development (R&D) expenses dropped 38% ($772,000) primarily due to the completion of the 2010 appendicitis clinical trial. Selling, General, and Administrative (SG&A) expenses decreased 15% ($280,000), driven by lower stock-based compensation and public company activity costs.
• Improved Gross Margin: Gross profit margin improved significantly to 87% from 54% in the prior year due to the absence of fixed production costs in the current period.
• Deferred Revenue Reclassification: A significant $900,000 milestone payment from Novartis was reclassified from deferred revenue to accrued expenses (liability) because a pilot study failed to meet success criteria, triggering a refund request.

Guidance, Outlook, Risks, and Contingencies

• Liquidity: Management believes current working capital ($7.1 million) is sufficient to meet near-term needs. Capital expenditures for the fiscal year are anticipated to be between $200,000 and $400,000, financed through working capital.
• Novartis Contingency: Novartis Animal Health has requested a refund of $900,000 following a failed pilot study. The company is reviewing the final report and plans to work with Novartis to understand the implications. This amount is currently recorded as an accrued expense.
• Legal Proceedings: The company is facing three active legal actions:
  • Mark Chipman v. AspenBio: Individual investor alleging fraud regarding AppyScore.
  • John Wolfe v. AspenBio: Purported class action regarding AppyScore disclosures.
  • Frank Trpisovsky v. Pusey: Shareholder derivative action against officers/directors alleging breach of fiduciary duty (currently stayed).
• Outlook: The company expects to continue incurring losses as it advances the AppyScore test toward FDA clearance and develops animal health products. Investment earnings are expected to be lower in 2011 due to lower cash balances and market conditions.

Key Facts for Investor Verification

• Novartis Refund Status: Verify the outcome of the review of the Novartis pilot study report and whether the $900,000 refund will be paid or if the agreement will be renegotiated/terminated.
• AppyScore Development: Monitor progress on FDA clearance for the AppyScore test, as failure to achieve this could lead to impairment of related patent costs.
• Legal Exposure: Track the status of the securities class action and individual lawsuits, specifically regarding the appointment of a lead plaintiff in the Wolfe case.
• Cash Burn Rate: Assess the sustainability of the current cash position ($8.1 million) given the continued net losses and anticipated R&D expenditures for the remainder of 2011.
• Customer Concentration: Note that one customer accounted for 73% of accounts receivable as of March 31, 2011.